Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial - PubMed (original) (raw)

Clinical Trial

. 2018 Aug 20;36(24):2532-2537.

doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10.

Ronglai Shen 1, Darren Buonocore 1, Zachary T Olah 1, Ai Ni 1, Michelle S Ginsberg 1, Gary A Ulaner 1, Michael Offin 1, Daniel Feldman 1, Todd Hembrough 1, Fabiola Cecchi 1, Sarit Schwartz 1, Nick Pavlakis 1, Stephen Clarke 1, Helen H Won 1, Edyta B Brzostowski 1, Gregory J Riely 1, David B Solit 1, David M Hyman 1, Alexander Drilon 1, Charles M Rudin 1, Michael F Berger 1, Jose Baselga 1, Maurizio Scaltriti 1, Maria E Arcila 1, Mark G Kris 1

Affiliations

Clinical Trial

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

Bob T Li et al. J Clin Oncol. 2018.

Erratum in

Abstract

Purpose Human epidermal growth factor receptor 2 ( HER2, ERBB2)-activating mutations occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in a cohort of patients with HER2-mutant lung cancers as part of a phase II basket trial. Patients and Methods Patients received ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. The primary end point was overall response rate using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A Simon two-stage optimal design was used. Other end points included progression-free survival and toxicity. HER2 testing was performed on tumor tissue by next generation sequencing, fluorescence in situ hybridization, immunohistochemistry, and protein mass spectrometry. Results We treated 18 patients with advanced HER2-mutant lung adenocarcinomas. The median number of prior systemic therapies was two (range, zero to four prior therapies). The partial response rate was 44% (95% CI, 22% to 69%), meeting the primary end point. Responses were seen in patients with HER2 exon 20 insertions and point mutations in the kinase, transmembrane, and extracellular domains. Concurrent HER2 amplification was observed in two patients. HER2 immunohistochemistry ranged from 0 to 2+ and did not predict response, and responders had low HER2 protein expression measured by mass spectrometry. The median progression-free survival was 5 months (95% CI, 3 to 9 months). Toxicities included grade 1 or 2 infusion reactions, thrombocytopenia, and elevated hepatic transaminases. No patient stopped therapy as a result of toxicity or died on study. Conclusion Ado-trastuzumab emtansine is an active agent in patients with HER2-mutant lung cancers. This is the first positive trial in this molecular subset of lung cancers. Further use and study of this agent are warranted.

Trial registration: ClinicalTrials.gov NCT02675829.

PubMed Disclaimer

Figures

Fig 1.

Fig 1.

Waterfall plot of best response. RECIST, Response Evaluation Criteria in Solid Tumors.

Fig 2.

Fig 2.

Swimmers plot of progression-free survival.

Fig A1.

Fig A1.

Basket trial schema. CLIA, Clinical Laboratory Improvement Amendments; FISH, fluorescent in situ hybridization; IV, intravenous; NGS, next-generation sequencing; RECIST, Response Evaluation Criteria in Solid Tumors.

Fig A2.

Fig A2.

Progression-free survival (PFS) of patients with _HER2_-mutant lung cancers (N = 18). The median PFS for all patients was 5 months (95% CI, 3 to 9 months), and median PFS for the responders was 6 months (95% CI, 4 months to not reached).

Similar articles

Cited by

References

    1. Stephens P, Hunter C, Bignell G, et al. : Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004 - PubMed
    1. Cancer Genome Atlas Research Network : Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-550, 2014 - PMC - PubMed
    1. Kris MG, Johnson BE, Berry LD, et al. : Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998-2006, 2014 - PMC - PubMed
    1. Wang SE, Narasanna A, Perez-Torres M, et al. : HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38, 2006 - PubMed
    1. Greulich H, Kaplan B, Mertins P, et al. : Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 109:14476-14481, 2012 - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources